We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,280

Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • April 9 2018

Lawmakers return today to Capitol Hill after a two-week recess, and multiple committees in both the House and Senate are poised to examine the opioid


Healthcare: What’s in the 2018 Omnibus Appropriations Law?
  • Morgan Lewis & Bockius LLP
  • USA
  • March 30 2018

The recently passed omnibus appropriations bill includes extensive funding, often at higher amounts than in fiscal year 2017, for many US healthcare


Anticipating This Year's HIPAA Enforcement Trends
  • Jenner & Block LLP
  • USA
  • February 26 2018

We are a year into a new presidential administration, and yet it seems we are asking the same question that we were at this juncture last year: What


Washington Healthcare Update - Feb 19, 2018
  • McGuireWoods LLP
  • USA
  • February 19 2018

While the President’s budget is not likely to be acted upon by Congress, it does signal what the administration’s priorities areas well as what


Washington Healthcare Update - Feb 5, 2018
  • McGuireWoods LLP
  • USA
  • February 5 2018

The chairman of the House Appropriations Committee, Rodney Frelinghuysen, announced he will retire at the end of his term. The 12-term New Jersey


As Congress Struggles With ACA Repeal, Trump Administration Moves Forward With Regulatory Reform
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • January 23 2018

The Trump administration and Republican-led Congress spent substantial time and political capital in 2017 on efforts to repeal and replace the


FDA's Evolving Regulation of Artificial Intelligence in Digital Health Products
  • Jones Day
  • USA
  • January 22 2018

FDA has been grappling with regulation of rapidly advancing digital products, including artificial intelligence. While Congress and FDA have provided


Sandoz v Amgen: An update
  • Bristows LLP
  • USA
  • January 9 2018

In our most recent publication, the Bristows' Biotech Review (Page 3), we reported on the US Supreme Court decision which, at the time, was the latest


What Could Happen to Imports If Government Shuts Down: 2017 Version
  • Arent Fox LLP
  • USA
  • December 15 2017

Based on recent activity in Congress, the possibility of a shutdown of US federal government activities for at least a brief period of time is looming


Congressional Hearings Focus on Health Policy Issues
  • Reed Smith LLP
  • USA
  • November 29 2017

A number of Congressional panels have scheduled or held recent hearings on health policy issues, including the following